These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25888271)

  • 21. Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis.
    Kourie HR; Antoun J; Bteich F; Jalkh A; Ghosn M
    Gulf J Oncolog; 2016 May; 1(21):67-9. PubMed ID: 27250892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological properties of abiraterone acetate (ZYTIGA® tablet 250 mg), a new drug for the treatment of castration-resistant prostate cancer, and results of its clinical studies].
    Iwata M; Tsutsumi K; Harada Y
    Nihon Yakurigaku Zasshi; 2015 May; 145(5):260-5. PubMed ID: 25958914
    [No Abstract]   [Full Text] [Related]  

  • 23. Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
    Suzman D; Eisenberger M
    Eur Urol; 2014 Nov; 66(5):826-8. PubMed ID: 24751214
    [No Abstract]   [Full Text] [Related]  

  • 24. Abiraterone-Associated Fulminant Liver Failure.
    Singh P; Sinha A; Lama Tamang TG; Chandra AB; Huang YJ
    Am J Ther; 2018; 25(4):e505-e506. PubMed ID: 28452846
    [No Abstract]   [Full Text] [Related]  

  • 25. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.
    Woo HH; Begbie S; Gogna K; Mainwaring PN; Murphy DG; Parnis F; Steer C; Davis ID
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):228-36. PubMed ID: 25132163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer: Interfering with abiraterone metabolism to optimize therapy.
    Thoma C
    Nat Rev Urol; 2016 Jul; 13(7):370. PubMed ID: 27245501
    [No Abstract]   [Full Text] [Related]  

  • 28. Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Elkon JM; Millett RL; Millado KF; Lin J
    Expert Opin Pharmacother; 2018 Apr; 19(5):507-509. PubMed ID: 29494266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
    Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Some questions about abiraterone, breakfast and public funding].
    Moreno Gómez Á; Abajo Del Álamo C; Catalá Pindado MÁ; Godoy Díez M
    Farm Hosp; 2015 Mar; 39(2):120-1. PubMed ID: 25817093
    [No Abstract]   [Full Text] [Related]  

  • 33. Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.
    Gunduz S; Bozcuk H; Yıldız M; Goksu SS; Uysal M; Arslan D; Tatlı AM; Mutlu H; Coşkun HS; Ozdogan M
    Indian J Cancer; 2015; 52(4):658-60. PubMed ID: 26960509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
    Conteduca V; Caffo O; Derosa L; Veccia A; Petracci E; Chiuri VE; Santoni M; Santini D; Fratino L; Maines F; Testoni S; De Giorgi U
    Prostate; 2015 Sep; 75(12):1329-38. PubMed ID: 25982919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world experience with abiraterone.
    Dahut WL; Madan RA
    Lancet Oncol; 2014 Oct; 15(11):1188-90. PubMed ID: 25242047
    [No Abstract]   [Full Text] [Related]  

  • 37. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
    Verzoni E; De Giorgi U; Derosa L; Caffo O; Boccardo F; Facchini G; Porcu L; De Vincenzo F; Zaniboni A; Chiuri VE; Fratino L; Santini D; Adamo V; De Vivo R; Dinota A; Messina C; Ricotta R; Caserta C; Scavelli C; Susi M; Tartarone A; Surace G; Mosca A; Bruno M; Barni S; Grassi P; Procopio G
    Oncotarget; 2016 Jun; 7(26):40085-40094. PubMed ID: 27223078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.
    Friedlander TW; Graff JN; Zejnullahu K; Anantharaman A; Zhang L; Paz R; Premasekharan G; Russell C; Huang Y; Kim W; Aggarwal RR; Lin AM; Fong L; Alumkal JJ; Beer TM; Sharifi N; Alyamani M; Dittamore R; Small EJ; Paris PL; Ryan CJ
    Clin Genitourin Cancer; 2017 Dec; 15(6):733-741.e1. PubMed ID: 28655452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.